Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer Research

• Publication date

  2002-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 11956082
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

  2001cited by this paper
• Specific protection against breast cancers by cyclin D1 ablation

  2001cited by this paper
• Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

  2001cited by this paper
• Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo *

  2001cited by this paper
• Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway

  2000cited by this paper
• Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol.

  2000cited by this paper
• ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency

  2000cited by this paper
• Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.

  1999cited by this paper
• Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization.

  1998cited by this paper
• Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

  1998cited by this paper
• Activation of Neu (ErbB-2) Mediated by Disulfide Bond-Induced Dimerization Reveals a Receptor Tyrosine Kinase Dimer Interface

  1998cited by this paper
• Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation

  1997cited by this paper
• Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice

  1994cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

  1986cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• Antineoplastic Agents: the Importance of Sequence of Administration'

  year unknowncited by this paper

• Pan Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer

  2023cites this paper
• Novel Therapies to Overcome HER2 Therapy Resistance in Breast Cancer

  2019cites this paper
• JUNB promotes the survival of Flavopiridol treated human breast cancer cells.

  2014cites this paper
• Signaling Networks as Possible Therapeutic Implications in Breast Cancer

  2014cites this paper
• Resveratrol suppresses the proliferation of breast cancer cells by inhibiting fatty acid synthase signaling pathway.

  2014cites this paper
• Prerequisite Genetic Traits for Metastasis

  2013cites this paper
• Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.

  2013cites this paper
• New developments in the treatment of HER2-positive breast cancer.

  2012cites this paper
• Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically

  2012cites this paper
• Epidermal growth factor-stimulated human cervical cancer cell growth is associated with EGFR and cyclin D1 activation, independent of COX-2 expression levels.

  2012cites this paper
• New developments in the treatment of HER 2-positive breast cancer

  2012cites this paper
• Cyclin-dependent kinase inhibition by flavoalkaloids.

  2012cites this paper
• Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.

  2011cites this paper
• Molecular-targeted therapy for cancer and nanotechnology.

  2010cites this paper
• Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy.

  2010cites this paper
• Targeting Cyclin-Dependent Kinases for Cancer Therapy

  2010cites this paper
• Crosstalk Between Leptin Receptor and IGF-IR in Breast Cancer: A Potential Mediator of Chemoresistance

  2009cites this paper
• Cell cycle alterations and 11q13 amplification in breast cancer -prediction of adjuvant treatment response

  2009cites this paper
• Flaxseed and pure secoisolariciresinol diglucoside, but not flaxseed hull, reduce human breast tumor growth (MCF-7) in athymic mice.

  2009cites this paper
• Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy.

  2009cites this paper
• An efficient method for identifying statistical interactors in gene association networks.

  2009cites this paper
• Circulating Tumor Cells in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab and Chemotherapy

  2009cites this paper
• Fundamentals of Cancer Cell Biology and Molecular Targeting

  2008cites this paper
• Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents

  2008cites this paper
• Dietary Flaxseed Interaction With Tamoxifen Induced Tumor Regression in Athymic Mice With MCF-7 Xenografts by Downregulating the Expression of Estrogen Related Gene Products and Signal Transduction Pathways

  2007cites this paper
• Herceptin: mechanisms of action and resistance.

  2006cites this paper
• From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer

  2006cites this paper
• Recent progress in the discovery and development of cyclin-dependent kinase inhibitors

  2005cites this paper
• Preclinical Modeling of Combination Treatments: Fantasy or Requirement?

  2005cites this paper
• Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance

  2005cites this paper
• Antitumor activity of HER-2 inhibitors.

  2005cites this paper
• Flavopiridol Inhibits NF-κB Activation Induced by Various Carcinogens and Inflammatory Agents through Inhibition of IκBα Kinase and p65 Phosphorylation

  2004cites this paper
• Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.

  2004cites this paper
• Regulatory Nodes That Integrate and Coordinate Signaling as Potential Targets for Breast Cancer Therapy

  2004cites this paper
• Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9.

  2004cites this paper
• Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci.

  2004cites this paper
• Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer

  2004cites this paper
• Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications.

  2004cites this paper
• Combining flavopiridol with various signal transduction inhibitors.

  2004cites this paper
• The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer.

  2004cites this paper
• Cyclin-dependent kinase inhibitors.

  2003cites this paper
• Growth factor receptors in breast cancer: potential for therapeutic intervention.

  2003cites this paper
• The pipeline of new anticancer agents for breast cancer treatment in 2003.

  2003cites this paper
• HER-2-targeted therapy: lessons learned and future directions.

  2003cites this paper
• Cyclin dependent kinase inhibitors

  2003cites this paper
• Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer.

  2003influential citation
• Long-term exposure to beta-hexachlorocyclohexane (beta-HCH) promotes transformation and invasiveness of MCF-7 human breast cancer cells.

  2003cites this paper
• resistant to STI 571 cells sensitive and + deacetylase inhibitors to induce apoptosis in Bcr / Abl

  2003cites this paper
• Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.

  2003cites this paper
• Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.

  2003cites this paper
• The Prolyl Isomerase Pin 1 in Breast Development and Cancer

  2003cites this paper
• Issues and progress with protein kinase inhibitors for cancer treatment

  2003cites this paper
• The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

  2003cites this paper
• Long-term exposure to β-hexachlorocyclohexane (β-HCH) promotes transformation and invasiveness of MCF-7 human breast cancer cells

  2003cites this paper
• Novel pharmacological approaches in the treatment of breast cancer

  2003influential citation
• The prolyl isomerase Pin1 in breast development and cancer

  2003cites this paper
• Functional relationship and gene ontology classification of breast cancer biomarkers.

  2003cites this paper
• Functional Relationship and Gene Ontology Classification of Breast Cancer Biomarkers

  2003cites this paper
• Coadministration of UCN-01 with MEK1/2 Inhibitors Potently Induces Apoptosis in

  2002cites this paper
• The RB and p53 pathways in cancer.

  2002cites this paper
• Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.

  2002cites this paper
• Flavopiridol Potentiates STI 571-induced Mitochondrial Damage and Apoptosis in BCR-ABL-positive Human Leukemia Cells 1

  2002cites this paper
• HER 2 HER 2 antibodies Trastuzumab Pertuzumab TDM 1 HER 2 tyrosine kinase inhibitors lapatinib

  year unknowncites this paper